GSK is win­ning 70% of the RSV mar­ket, while Pfiz­er's launch has left it ‘dis­ap­point­ed’ so far

GSK has tak­en over a sig­nif­i­cant share of what’s ex­pect­ed to be a multi­bil­lion-dol­lar mar­ket for RSV pre­ven­ta­tives, turn­ing its vac­cine in­to a block­buster in the first year on the mar­ket while com­peti­tors strug­gle.

Like GSK, Pfiz­er al­so had its RSV vac­cines ap­proved this year, and Sanofi and As­traZeneca’s pre­ven­tive an­ti­body was cleared by the FDA in Ju­ly. The North­ern Hemi­sphere is in the height of RSV sea­son, and there’s been sig­nif­i­cant de­mand for the prod­ucts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.